•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Lian SGP Holding Pte. Ltd. has announced the results of its public tender offer for Imexpharm Joint Stock Company (ticker: IMP, HoSE). The company purchased 104.5 million IMP shares from 109 investors, increasing its ownership to 67.87% of Imexpharm’s charter capital.
Previously, Lian SGP Holding Pte. Ltd. registered to tender for more than 120 million IMP shares, equivalent to 77.94% of charter capital. The tender offer price was set at VND 57,400 per share.
By the end of the tender period on April 23, Lian SGP Holding Pte. Ltd. acquired 104.5 million IMP shares. Based on the offer price of VND 57,400 per share, the deal is estimated to have cost nearly VND 6 trillion.
Lian SGP Holding Pte. Ltd. is an indirect subsidiary wholly owned by Livzon Pharmaceutical Group, a major Chinese pharmaceutical conglomerate.
Livzon Pharmaceutical Group was established in 1985 and has registered capital of over CNY 935 million. The group operates in more than 30 countries, including the U.S., EU, Korea, Japan, and Southeast Asia, and is among the 25 largest pharmaceutical companies in China. Its activities cover research, manufacturing, and development of medicines, new drugs, traditional Chinese medicines, and raw materials.
Livzon’s stated investment stance for Imexpharm includes maintaining a stable production and business strategy while expanding the portfolio of high-tech products on EU-GMP compliant production lines.
In parallel with the tender offer, three SK Group ecosystem members registered to sell IMP shares.
Several Imexpharm executives also registered to sell shares:
These transactions are expected to take place from April 15 to May 14, 2026, for family financial reasons.
Earlier, another deputy general director of Imexpharm, Mr. Huynh Van Nhung, registered to sell 80,000 IMP shares during April 16 to May 15, 2026, also for family financial reasons. If completed, his holding would be reduced to 100,000 shares, equivalent to 0.065% of Imexpharm’s charter capital.
Imexpharm held its 2026 annual general meeting on April 22. The meeting approved revenue and pre-tax profit targets of VND 3,200 billion and VND 502 billion, representing growth of about 9.8% and 12.5%, respectively.
The company also planned a 2026 dividend payout of 5%–8%.
To achieve these targets, Imexpharm plans to expand its high-tech product portfolio within the EU-GMP segment and strengthen its presence in the northern market by increasing distribution through pharmacy chains.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
